These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2210615)

  • 1. Status report on the US human growth hormone recipient follow-up study.
    Mills JL; Fradkin J; Schonberger L; Gunn W; Thomson RA; Piper J; Wysowski D; Brown P
    Horm Res; 1990; 33(2-4):116-9; discussion 120. PubMed ID: 2210615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States.
    Fradkin JE; Schonberger LB; Mills JL; Gunn WJ; Piper JM; Wysowski DK; Thomson R; Durako S; Brown P
    JAMA; 1991 Feb; 265(7):880-4. PubMed ID: 1992185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977.
    Abrams JY; Schonberger LB; Belay ED; Maddox RA; Leschek EW; Mills JL; Wysowski DK; Fradkin JE
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1666-9. PubMed ID: 21816775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creutzfeldt-Jakob disease after administration of human growth hormone.
    Powell-Jackson J; Weller RO; Kennedy P; Preece MA; Whitcombe EM; Newsom-Davis J
    Lancet; 1985 Aug; 2(8449):244-6. PubMed ID: 2862420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degenerative neurologic disease in patients formerly treated with human growth hormone. Report of the Committee on Growth Hormone Use of the Lawson Wilkins Pediatric Endocrine Society, May 1985.
    J Pediatr; 1985 Jul; 107(1):10-2. PubMed ID: 3891943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human growth hormone and Creutzfeldt-Jakob disease.
    Zekauskas S; Boggs MB; Wilson DP
    J Okla State Med Assoc; 1990 Sep; 83(9):447-8. PubMed ID: 2280278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients.
    Mills JL; Schonberger LB; Wysowski DK; Brown P; Durako SJ; Cox C; Kong F; Fradkin JE
    J Pediatr; 2004 Apr; 144(4):430-6. PubMed ID: 15069388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?
    Boyd A; Klug GM; Schonberger LB; McGlade A; Brandel JP; Masters CL; Collins SJ
    Med J Aust; 2010 Sep; 193(6):366-9. PubMed ID: 20854243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human growth hormone Creutzfeld Jakob disease litigation.
    Owen R
    Med Leg J; 1997; 65 ( Pt 2)():46-64. PubMed ID: 9241994
    [No Abstract]   [Full Text] [Related]  

  • 10. Creutzfeldt-Jakob disease following pituitary-derived human growth hormone therapy: a new American case.
    Marzewski DJ; Towfighi J; Harrington MG; Merril CR; Brown P
    Neurology; 1988 Jul; 38(7):1131-3. PubMed ID: 3290703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiologic survey of patients treated with growth hormone in France in the period 1959-1990: preliminary results.
    Job JC; Maillard F; Goujard J
    Horm Res; 1992; 38 Suppl 1():35-43. PubMed ID: 1295811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of children with short stature with human growth hormone and its potential risks].
    Sizonenko PC
    Arch Fr Pediatr; 1993 May; 50(5):369-74. PubMed ID: 8239885
    [No Abstract]   [Full Text] [Related]  

  • 13. Creutzfeldt-Jakob disease after pituitary-derived human growth hormone therapy: two cases with valine 129 homozygous genotype.
    Masson C; Delalande I; Deslys JP; Hénin D; Fallet-Bianco C; Dormont D; Leys D
    Neurology; 1994 Jan; 44(1):179-80. PubMed ID: 7904734
    [No Abstract]   [Full Text] [Related]  

  • 14. [Creutzfeldt-Jakob disease in 4 children treated with growth hormone].
    Billette de Villemeur T; Gourmelen M; Beauvais P; Rodriguez D; Vaudour G; Deslys JP; Dormont D; Richard P; Richardet JM
    Rev Neurol (Paris); 1992; 148(5):328-34. PubMed ID: 1448646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of risks related to human growth hormone (hGH) treatment. Results of an epidemiologic survey conducted in France of patients treated from 1959 to 1985].
    Goujard J; Entat M; Maillard F; Mugnier E; Rappaport R; Job JC
    Arch Fr Pediatr; 1989; 46(6):411-6. PubMed ID: 2675793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone.
    Irwin DJ; Abrams JY; Schonberger LB; Leschek EW; Mills JL; Lee VM; Trojanowski JQ
    JAMA Neurol; 2013 Apr; 70(4):462-8. PubMed ID: 23380910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A further British case of growth hormone induced Creutzfeldt-Jakob disease.
    Ellis CJ; Katifi H; Weller RO
    J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1200-2. PubMed ID: 1479400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human pituitary growth hormone and Creutzfeldt-Jakob disease.
    Preece M
    Horm Res; 1993; 39(3-4):95-8. PubMed ID: 8262483
    [No Abstract]   [Full Text] [Related]  

  • 19. [Creutzfeldt-Jakob disease after treatment with human extracted growth hormone. A clinicopathological study].
    Delisle MB; Fabre N; Rochiccioli P; Doerr-Schott J; Rumeau JL; Bes A
    Rev Neurol (Paris); 1993; 149(10):524-7. PubMed ID: 8023064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone.
    Cali I; Miller CJ; Parisi JE; Geschwind MD; Gambetti P; Schonberger LB
    Acta Neuropathol Commun; 2015 Jun; 3():37. PubMed ID: 26108478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.